Other
Oral overactive bladder medication: oxybutynin, tolterodine, solifenacin
Oral anticholinergic
Other names: oxybutynin, Ditropan, tolterodine, Detrol, solifenacin, Vesicare
FAA guidance
Do not issue.
Examiner
Do not issue: the examiner cannot issue a certificate
FAA label
DO NOT ISSUE
The FAA's Do Not Issue list, under oral anticholinergics, names over-active bladder medications with tertiary structure that carry strong warnings about the potential for sedation and impaired cognition — tolterodine, oxybutynin and solifenacin — and the FAA's table says the examiner should defer the exam; it also says do not issue a medical certificate.
Track your medicationsMore detail: Oral overactive bladder medication: oxybutynin, tolterodine, solifenacinThe rest of Crosscheck's reading, in plain wordsOpen
The oxybutynin skin patch (Oxytrol for women) has its own entry.
Show the FAA's words: Oral overactive bladder medication: oxybutynin, tolterodine, solifenacinThe official FAA wording: one passage, each with its document and dateOpen
DO NOT ISSUE (DNI) MEDICATIONS
If the applicant is taking any of the following medications, AMEs should DEFER the exam. DO NOT issue a medical certificate to applicants who are using any of the following drug classes or medications for any condition:
ANTICHOLINERGICS (ORAL)
atropine
Over-active bladder (OAB) medications with tertiary structure that carry strong warnings about the potential for sedation and impaired cognition:
tolterodine (Detrol)
oxybutynin (Ditropan)
solifenacin (Vesicare)